Connection

JOANNA JANKOWSKY to Humans

This is a "connection" page, showing publications JOANNA JANKOWSKY has written about Humans.
Connection Strength

0.281
  1. TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy. Acta Neuropathol. 2024 03 25; 147(1):61.
    View in: PubMed
    Score: 0.023
  2. Temporal and spatially controlled APP transgene expression using Cre-dependent alleles. Dis Model Mech. 2022 05 01; 15(5).
    View in: PubMed
    Score: 0.020
  3. Gene therapy using A? variants for amyloid reduction. Mol Ther. 2021 07 07; 29(7):2294-2307.
    View in: PubMed
    Score: 0.019
  4. Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease. Hum Mol Genet. 2019 06 15; 28(12):2014-2029.
    View in: PubMed
    Score: 0.017
  5. Practical considerations for choosing a mouse model of Alzheimer's disease. Mol Neurodegener. 2017 12 22; 12(1):89.
    View in: PubMed
    Score: 0.015
  6. Discrete Pools of Oligomeric Amyloid-? Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. Am J Pathol. 2018 03; 188(3):739-756.
    View in: PubMed
    Score: 0.015
  7. Neuronal overexpression of human VAPB slows motor impairment and neuromuscular denervation in a mouse model of ALS. Hum Mol Genet. 2016 11 01; 25(21):4661-4673.
    View in: PubMed
    Score: 0.014
  8. Impaired Recall of Positional Memory following Chemogenetic Disruption of Place Field Stability. Cell Rep. 2016 07 19; 16(3):793-804.
    View in: PubMed
    Score: 0.013
  9. Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction. PLoS One. 2016; 11(4):e0153724.
    View in: PubMed
    Score: 0.013
  10. Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex. Brain Struct Funct. 2016 05; 221(4):2231-49.
    View in: PubMed
    Score: 0.012
  11. Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci. 2014 Mar 12; 34(11):3826-40.
    View in: PubMed
    Score: 0.011
  12. Wild-type neural progenitors divide and differentiate normally in an amyloid-rich environment. J Neurosci. 2013 Oct 30; 33(44):17335-41.
    View in: PubMed
    Score: 0.011
  13. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol Neurodegener. 2012 Jun 18; 7:28.
    View in: PubMed
    Score: 0.010
  14. Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J Neurosci. 2007 Jun 20; 27(25):6771-80.
    View in: PubMed
    Score: 0.007
  15. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem. 2007 Aug 03; 282(31):22707-20.
    View in: PubMed
    Score: 0.007
  16. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005 Dec; 2(12):e355.
    View in: PubMed
    Score: 0.006
  17. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci. 2005 May 25; 25(21):5217-24.
    View in: PubMed
    Score: 0.006
  18. APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging. 2004 Aug; 25(7):885-92.
    View in: PubMed
    Score: 0.006
  19. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004 Jan 15; 13(2):159-70.
    View in: PubMed
    Score: 0.006
  20. An automated respiratory data pipeline for waveform characteristic analysis. J Physiol. 2023 11; 601(21):4767-4806.
    View in: PubMed
    Score: 0.006
  21. TMEM106B regulates microglial proliferation and survival in response to demyelination. Sci Adv. 2023 05 05; 9(18):eadd2676.
    View in: PubMed
    Score: 0.005
  22. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001 Jun; 17(6):157-65.
    View in: PubMed
    Score: 0.005
  23. The role of cytokines and growth factors in seizures and their sequelae. Prog Neurobiol. 2001 Feb; 63(2):125-49.
    View in: PubMed
    Score: 0.005
  24. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest. 2020 04 01; 130(4):1912-1930.
    View in: PubMed
    Score: 0.004
  25. Amyloid-? plaques disrupt axon initial segments. Exp Neurol. 2016 07; 281:93-8.
    View in: PubMed
    Score: 0.003
  26. Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease. J Neurosci. 2016 Jan 13; 36(2):577-89.
    View in: PubMed
    Score: 0.003
  27. Quaternary Structure Defines a Large Class of Amyloid-? Oligomers Neutralized by Sequestration. Cell Rep. 2015 Jun 23; 11(11):1760-71.
    View in: PubMed
    Score: 0.003
  28. NF?B-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron. 2015 Jan 07; 85(1):101-115.
    View in: PubMed
    Score: 0.003
  29. Cerebral vascular leak in a mouse model of amyloid neuropathology. J Cereb Blood Flow Metab. 2014 Oct; 34(10):1646-54.
    View in: PubMed
    Score: 0.003
  30. Genetic modulation of soluble A? rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci. 2014 Jun 04; 34(23):7871-85.
    View in: PubMed
    Score: 0.003
  31. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. Behav Brain Res. 2012 Apr 15; 229(2):308-19.
    View in: PubMed
    Score: 0.002
  32. GABA transporter function, oligomerization state, and anchoring: correlates with subcellularly resolved FRET. J Gen Physiol. 2009 Dec; 134(6):489-521.
    View in: PubMed
    Score: 0.002
  33. Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. Hum Mol Genet. 2001 Oct 15; 10(22):2525-37.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.